Naratriptan

Naratriptan (trade names include Amerge) is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. It is a selective 5-HT₁ receptor subtype agonist. In the United States, the Food and Drug Administration (FDA) approved naratriptan on February 11, 1998.